Do you have to take HRT after both ovaries are removed?

Not 'have to.' For women under about 45 with no contraindication, guidance generally supports offering it — for symptoms and to protect bone during years of missing estrogen. It's a medical decision made with a clinician, and it's ultimately your choice.

Do you need HRT after just one ovary is removed?

Not automatically. A functioning remaining ovary can keep producing hormones. If new menopausal symptoms appear, that's worth an evaluation rather than an assumption.

Do you need progesterone if you don't have a uterus?

Usually not for lining protection after a confirmed total hysterectomy. But a subtotal (supracervical) hysterectomy can leave residual lining tissue, and an endometriosis history often calls for combined therapy even without a uterus.

How soon after oophorectomy can HRT start?

There's no single interval. For benign surgery with final pathology and no contraindication, prompt initiation is commonly supported once your surgical team clears it. For endometriosis, no universal interval is established. For pending pathology or cancer, your treating team decides.

How long do you stay on HRT after early ovary removal?

Guidance commonly supports continuing until around the usual menopause age (about 51-52) when there's no contraindication, then reassessing. It doesn't have to be stopped automatically at a set age.

Is HRT safe after oophorectomy if I've had breast cancer?

Systemic HRT is generally not recommended after breast cancer; any exceptional use is oncology-led. For vaginal or urinary symptoms, nonhormonal treatments come first, with low-dose vaginal estrogen considered after those fail, in coordination with your oncology team.

Is HRT safe after a BRCA risk-reducing oophorectomy?

For carriers with no personal cancer history, it's commonly considered. A 2026 cohort of 919 women found no increased breast cancer risk with HRT after this surgery; a reduction appeared in the per-year duration analysis for estrogen-only use, not in the simple ever-use comparison. It's observational. Coordinate with your high-risk clinic, and note that an intact uterus still requires a progestogen.

Patch or pill after oophorectomy?

Many clinicians favor a patch or gel when clot risk matters — oral estrogen is associated with higher VTE risk in observational data. The stroke evidence is weaker. Pills remain reasonable for many women. It depends on your risk history.

Do you need testosterone after oophorectomy?

Not routinely. It may be considered for persistent, distressing low sexual desire after a full assessment. Evidence doesn't support it for energy, mood, or general well-being. There's no FDA-approved testosterone product for women in the U.S., it's off-label, and it's a Schedule III controlled substance requiring a prescription and monitoring.

Do I need blood tests before starting?

Not necessarily. If your records confirm both ovaries were removed, a hormone panel isn't needed to prove it. Tests should answer a specific question your clinician has.

Can an online provider manage HRT after oophorectomy?

Often yes for uncomplicated cases — if the service handles surgical menopause, reviews your records, serves your state, and provides real follow-up. If your case is cancer-, BRCA-, or endometriosis-complex, start with an in-person specialist.

Is compounded HRT the same as FDA-approved HRT?

No. Compounded hormones are prepared by a compounding pharmacy or outsourcing facility and are not FDA-approved. The FDA doesn't verify their safety, effectiveness, or quality before marketing. They aren't equivalent to approved products.

Will insurance cover it?

It depends on your plan, the product, the formulary, your pharmacy benefit, prior authorization, and whether the medication is compounded. Verify the actual product and billing route with your plan before treatment starts.

Heavy bleeding, fever, chest pain, or severe worsening pain after surgery — contact your surgical team or urgent care immediately, per your discharge instructions.

HRT After Oophorectomy: Do You Need It, and What Changes the Answer?

The HRT Index Editorial TeamIndependent women's health research

Published: May 15, 2026Last reviewed: July 2026

Editorial research — not medically reviewed by a clinician. Why this label

HRT after oophorectomy is not automatic when one ovary is removed — a working remaining ovary may keep making hormones. When both ovaries are removed before natural menopause, it usually deserves a prompt discussion. Guidance is clearest before age 45, where hormone therapy should generally be offered unless there’s a medical reason not to, and continued to about age 51–52 before reassessing.

That’s the short version. Now the part nobody handed you at discharge: five things change the route. Whether one ovary or both came out. Whether any uterine lining tissue is still there. How old you were. Why the surgery happened, and what the pathology showed. And your own medical history. Your operative report and pathology results hold most of those answers.

Written for readers in the United States. FDA status, controlled-substance rules, insurance terms, and provider availability are U.S.-specific. Some clinical sources are international and are labeled accordingly.

The 30-second answer

Last verified: July 15, 2026

Quick-answer table: HRT after oophorectomy by situation
Your situation	The bottom line
One ovary removed, the other appears to work	Not automatic. A functioning ovary may keep making hormones. Symptoms still deserve evaluation.
Both ovaries removed before natural menopause, no contraindication or specialist-first history	A prompt clinical review is appropriate. Before 45, guidance generally supports offering systemic hormone therapy through the usual menopause age.
Uterine lining tissue remains	Systemic estrogen generally needs a progestogen, or another accepted way to protect the lining.
Endometriosis, cancer, BRCA, or unresolved pathology	The simple rules don’t apply. Specialist first — not a general online sign-up.

This page is for you if…

One or both ovaries were removed or surgery is scheduled
You’re unsure whether this means instant menopause
You want to know whether your uterus changes the plan
You want to walk into your first appointment prepared

This page is not a substitute for…

Your surgeon’s post-op instructions
Oncology review if cancer is suspected or diagnosed
Specialist review for complex endometriosis or a contraindication history
A prescription

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated.

The honest part

This page cannot tell you whether HRT is safe for you. No page can. And any page that gives every woman the same confident yes-or-no is skipping the facts that change the answer — one ovary or both, uterus or no uterus, your age, your pathology report, and your personal history with things like cancer, clots, or endometriosis.

Here’s why that should make you feel better, not worse: those facts aren’t mysterious. They’re written down. They’re in your operative report, your pathology results, and your own history. Once they’re in front of you, this stops being a fog and starts being a checklist.

The right starting point isn’t the same for every woman

The right online HRT provider depends on your symptoms, your age and whether you have a uterus, your medication route preference, your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Use The HRT Index’s Find My HRT Path tool to match your situation to the right starting point.

See your best-fit starting care route

About 90 seconds · No email required

The HRT after oophorectomy decision map

Version 1.0 — verified July 15, 2026

This map organizes current guidance into a routing framework. It does not decide whether HRT is safe or right for you. Where a column reflects a guideline, we say so. Where it reflects our editorial judgment, we say that too.

HRT after oophorectomy decision map
Your situation	What guidance generally supports	Lining / progestogen?	Editorial first care route	Evidence type
One ovary removed, other appears functional	Not automatic. A functioning ovary can keep producing hormones. Symptoms still warrant evaluation.	Only relevant if systemic estrogen is later considered and lining tissue remains.	Your gynecologist or a menopause-capable primary care clinician.	Procedure fact (Cleveland Clinic) + editorial routing
Both ovaries removed before 45	The clearest branch. Offer HRT unless contraindicated; continue to at least ~51.	Protect the lining if it remains.	Prompt menopause-capable visit; specialist first if any row below applies.	Guideline (BMS; ASRM/ESHRE POI; Menopause Society)
Both ovaries removed, ~45 to usual menopause age	Prompt individualized discussion is appropriate. Preventive-outcome evidence is less direct than before 45.	Depends on remaining lining.	Menopause-capable clinician.	Editorial synthesis — not a formal guideline age band
Both ovaries removed after natural menopause	The 'replace what you lost early' logic no longer applies the same way. Based on symptoms and individual risk.	Same lining rule for systemic estrogen.	Existing clinician or specialist, by complexity.	Editorial inference from age- and timing-based guidance
Uterus intact	Systemic estrogen generally requires adequate progestogen or another accepted lining-protection strategy.	Yes — central safety point.	Clinician who can prescribe and monitor combined therapy.	Guideline + FDA labeling
Confirmed total hysterectomy, no exception below	Estrogen-only systemic therapy is often considered — no lining to protect.	Not routinely needed for lining protection alone.	Menopause-capable clinician.	Guideline + FDA labeling
Subtotal/supracervical hysterectomy, or anatomy unclear	Don't assume estrogen-only. Residual lining tissue can remain.	Possibly yes.	Gynecology or menopause specialist, with your records.	Guideline (BMS) + editorial routing
Oophorectomy for endometriosis	Avoid automatic estrogen-only. Combined therapy generally favored, even after hysterectomy.	Can matter even without a uterus.	In-person menopause or gynecology specialist, ideally with endometriosis experience.	Guideline (ESHRE; BMS 2026); underlying evidence limited
Risk-reducing surgery for BRCA, no prior cancer	HRT is an option after RRSO. Estrogen-only used only where lining protection isn't required; intact uterus still needs a progestogen.	Uterus status still sets the regimen.	High-risk/genetics clinic or menopause specialist; online follow-up only when coordinated.	Observational cohort (JAMA Netw Open 2026); no international guideline exists
Personal history of breast or other hormone-sensitive cancer	Systemic HRT generally not recommended. Any exception is oncology-led.	Secondary to the oncology decision.	Oncology / your cancer team first.	Guideline (ACOG; Menopause Society)
Cancer suspected, pathology pending	Wait for the team reading your pathology before relying on a general HRT path.	Depends on final diagnosis.	Your surgeon or oncology team first.	Editorial safety routing informed by cancer exceptions in guidance

Find which row is youAnd whether online care is a reasonable first stop.

Does it matter if one ovary or both were removed?

Yes — this is the first fork. If only one ovary was removed and the other still functions, it can keep producing hormones, and HRT is not automatic. If both were removed before natural menopause, ovarian hormone production ends abruptly, and that’s when a hormone therapy conversation usually becomes important.

“Oophorectomy” just means removing an ovary. It comes in two very different forms:

Unilateral oophorectomy— one ovary removed. The other can often keep doing its job. Menstrual periods may continue if your uterus is still there. If your uterus was also removed, you won’t have periods regardless — which means you can’t use your cycle as a signal, and symptoms become the thing to watch.
Bilateral oophorectomy— both removed. Before your natural menopause, this causes surgical menopause (menopause triggered by surgery rather than age). The hormone drop is abrupt rather than gradual.

Don’t guess from the name of your surgery. Here’s how to decode what you were actually told — and what each phrase still leaves unanswered.

Operative report decoder

What the wording means, and the question it leaves open. This tells you what to ask — it cannot interpret your report clinically.

Operative report decoder table
If your report or surgeon says…	It means	The question still open
"Unilateral oophorectomy"	One ovary removed	Did the remaining ovary look healthy? Is it expected to keep working?
"Bilateral oophorectomy"	Both ovaries removed	Was this before my natural menopause? What's the HRT plan?
"Salpingo-oophorectomy"	Ovary and fallopian tube removed, one side	Same as unilateral — what about the other side?
"Bilateral salpingo-oophorectomy" (BSO)	Both ovaries and both tubes removed	This is surgical menopause if you hadn't gone through it yet. Who manages my hormones now?
"Total hysterectomy"	Uterus and cervix removed	Confirms no lining to protect — unless endometriosis is in my history.
"Subtotal" or "supracervical hysterectomy"	Uterine body removed, cervix left in place	Could any lining tissue remain? Do I still need a progestogen?
"Ovary preserved" / "ovarian conservation"	At least one ovary intentionally left	Is it functioning? Should I expect menopause later than usual?
Anything you can't find in writing	Unresolved	Request the operative report and pathology before anyone prescribes.

If you had one ovary removed and new hot flashes, night sweats, poor sleep, vaginal dryness, or mood changes show up, that’s worth an evaluation. Those can reflect reduced ovarian function — but they can also have non-ovarian causes like recovery, medication, thyroid problems, or anemia. A clinician sorts that out.

Do you usually need HRT after both ovaries are removed before menopause?

When both ovaries are removed before natural menopause, hormone therapy usually deserves a prompt discussion. The guidance is strongest before age 45: major bodies advise offering systemic HRT unless there’s a contraindication, and continuing to at least about age 51. Between 45 and the usual menopause age, a prompt individualized discussion is still appropriate, but the preventive evidence is less direct.

A commonly cited physiologic estimate is an approximately 80% decline in circulating estradiol and 50% decline in testosterone after bilateral oophorectomy (New England Journal of Medicine, Shifren et al. 2000). Unlike natural menopause, which unfolds over years, ovarian hormone production ends abruptly. That’s why symptoms can hit hard and fast — and why “just wait and see” is often poor advice for a younger woman.

What the guidelines actually say, by age

Assembled from four sources so you can see where they agree and where they don’t.

Guidelines on HRT after bilateral oophorectomy, by age
Age at bilateral surgery	What it’s called	Core position	Reassessment point	Evidence strength
Before 40	Premature ovarian insufficiency / premature menopause	Hormone therapy through the usual menopause age unless contraindicated	~51–52	Strongest consensus; longest window of missing estrogen
40–44	Early menopause	Offer HRT unless contraindicated; continue to at least 51	~51	Strong (BMS: offer to under-45s until at least 51)
45 to ~51	Surgical menopause near typical age	Prompt individualized discussion; symptoms and personal risk weigh more	~51–52	Similar counseling, but preventive-outcome evidence is less developed
After ~51–52	Post-natural-menopause surgery	Not a 'replace to 51' case. Based on symptoms, indication, timing, risk	Ongoing, individualized	Editorial inference from timing-based guidance

“I feel fine, so I don’t need it”doesn’t close the conversation for a younger woman. Some of the strongest reasons to consider HRT after early bilateral surgery — protecting bone during years of missing estrogen — don’t announce themselves with symptoms. That doesn’t mean every woman should start. It means the decision deserves a real discussion, not a shrug. It’s your choice to make; it should be an informed one.

And here’s what we won’t tell you: that HRT is proven to protect your heart or yourbrain. Hormone therapy is the principal replacement treatment after early ovarian hormone loss, and it’s established for treating hot flashes and night sweats and for preventing bone loss while it’s used. Guidelines also recommend it through the usual menopause age in premature and early menopause. But the cardiovascular and cognitive outcome evidence is largely observational — it doesn’t guarantee an individual result, and anyone promising you it does is selling something.

What happens if you don’t take HRT after both ovaries are removed?

Without hormone therapy after early bilateral oophorectomy, most women experience menopausal symptoms — often abrupt and severe — and bone loss is a documented concern during years of estrogen deprivation. Early bilateral oophorectomy is also associated in observational research with longer-term cardiovascular and cognitive concerns, though those associations don’t prove that treatment prevents any individual outcome.

The most concrete number comes from bone. In a 2011 cohort of women at high ovarian cancer risk who had risk-reducing surgery, DXA scans found low bone density (T-score ≤ −1.0) in 37 of 78 women (47%)who had at least 24 months of estrogen deprivation before age 50 — compared with 5 of 31 (16%) who had no such period of deprivation (British Journal of Cancer, Cooke et al. 2011). Read that precisely: it compared periods of estrogen deprivation, not a clean “HRT vs. no HRT” trial. It’s an observational subgroup analysis. It’s still the clearest signal available that going years without estrogen after early surgery has a measurable cost to bone.

Going without HRT is a legitimate choice — some women can’t take it, and some don’t want it. It just shouldn’t be a choice made by default, or because nobody explained the trade-off.

Do you need progesterone after oophorectomy?

The question isn’t whether your ovaries are gone — it’s whether uterine lining tissue is still there. If your uterus is intact, systemic estrogen generally needs a progestogen to protect the lining. After a confirmed total hysterectomy, estrogen alone is often appropriate. A partial hysterectomy or an endometriosis history can change that.

Plain version: estrogen tells the uterine lining to grow. Unopposed, that constant signal raises the risk of problems in the lining, including cancer. A progestogen— the umbrella term covering progesterone (the hormone your body makes) and progestins (lab-made versions that act like it) — keeps that in check.

This isn’t just our framing. When the FDA updated hormone therapy labels in February 2026, it removed several boxed-warning risks but kept the boxed warning about endometrial cancer specifically for systemic estrogen-alone products — precisely because unopposed estrogen and an intact uterus don’t mix.

What your anatomy means for lining protection

Progestogen requirement by anatomy
Your anatomy	Progestogen needed for lining protection?	The exception to check
Uterus intact	Yes, with systemic estrogen	None — this is the rule
Confirmed total hysterectomy	Not routinely	Endometriosis history (see below)
Subtotal / supracervical hysterectomy	Possibly — residual lining tissue can remain	Get the operative note before assuming
Not sure what was removed	Unresolved — don't assume	Request records first
Endometriosis history, any anatomy	Often yes, even without a uterus	Specialist call
Cancer history	Secondary to the oncology decision	Oncology-led

One note on the progestogen itself: observational evidence suggests micronized progesteronemay carry a lower clot risk than some synthetic progestins, though randomized comparative evidence is limited. No category is automatically “safer” or “more natural” for everyone — that’s a conversation, not a slogan.

If you had a subtotal hysterectomy and someone assumes estrogen-only is appropriate without checking, that’s the moment to speak up.

How does endometriosis change HRT after oophorectomy?

Endometriosis is estrogen-responsive, and residual disease can remain even after hysterectomy and removal of both ovaries. Guidelines therefore advise against automatically using estrogen-only therapy in women with an endometriosis history, and generally favor continuous combined therapy after surgical menopause — particularly where residual disease may remain.

This is the exception that catches people. You had a hysterectomy, so the “no uterus, no progestogen” rule should apply — except endometriosis tissue similar to the uterine lining can be sitting elsewhere in the pelvis, and removing your uterus doesn’t guarantee every deposit went with it.

What the guidance says — and what it doesn’t

Endometriosis guidance on HRT after oophorectomy
Source	Position
ESHRE (2022)	Advises against estrogen-only regimens in women with a history of endometriosis; supports combined treatment even after hysterectomy.
Reviews of current practice	Combined estrogen-progestogen (or tibolone, where available) preferred over unopposed estrogen; the concern is recurrence and, rarely, malignant transformation.
BMS (Feb 2026)	No agreed universal interval for starting HRT after surgical menopause in endometriosis; timing individualized by symptoms, residual disease, pathology, and the treating team.
What none of them can tell you	The absolute risk of recurrence or malignant transformation with different regimens. The evidence is small studies and case reports.

Two honest caveats. The evidence for combined therapy specifically in women who’ve already had a hysterectomy is weak — it rests on consensus and small observational data, not trials. And this is nota reason to be denied hormone therapy: guidance is equally clear that symptomatic women shouldn’t be refused HRT solely because of an endometriosis history, since the benefits often outweigh the theoretical risks.

The practical takeaway: if endometriosis is in your story, this belongs with a menopause or gynecology specialist who has your surgical details — not a quick online refill that treats you as a standard “no uterus” case.

Can you use HRT after BRCA risk-reducing oophorectomy?

For BRCA1/2 carriers with no personal history of cancer, hormone therapy after risk-reducing bilateral oophorectomy is commonly considered. A 2026 cohort found HRT after this surgery was not associated with increased breast cancer risk. The finding is observational, from a selected population, and no international guideline currently exists for HRT in BRCA carriers.

The first fork here is simple and non-negotiable: prior cancer, or no prior cancer. Everything below applies only to carriers who have not had breast cancer.

The 2026 study, in full

Regev-Sadeh et al., JAMA Network Open, April 2026 — what it found and what it can’t say.

JAMA Network Open 2026 BRCA cohort study details
Who	919 cancer-free women with BRCA1 (496) or BRCA2 (423) pathogenic variants, in Israel
Excluded	Anyone with prior cancer, or risk-reducing mastectomy before/within a year of surgery
Population note	828 of 919 (90.1%) carried one of three Ashkenazi founder variants
Mean age at surgery	47.6 years · Mean follow-up: 8.8 years
HRT use	381 (42%) ever used; 538 (58%) never
Breast cancers	144 (16%)
Ever-use result	Estrogen-only: HR 0.89 (95% CI, 0.48–1.63). Combined estrogen-progestin: HR 1.06 (95% CI, 0.67–1.68). Both confidence intervals cross 1 — neither shows a significant difference.
Duration result	Each year of estrogen-only HRT: HR 0.90 (0.81–0.99) overall; HR 0.87 (0.77–0.98) in BRCA1 — about a 10% and 13% reduction per year of use.
An unexpected finding	LNG-IUD use before surgery was associated with increased breast cancer risk (HR 1.69; 1.09–2.61), driven by BRCA1 carriers (HR 2.00; 1.18–3.36).
Limits	Retrospective and observational — residual confounding possible; recall bias; selection toward women engaged with medical care. Not a randomized trial.

Read that carefully, because the headline and the data differ. The simple “did you ever use HRT” analysis found no significant difference either way. The reduced risk in BRCA1 carriers appeared in the durationanalysis — per year of estrogen-only use. That’s a meaningful signal worth discussing with your clinician. It is not proof that estrogen prevents breast cancer.

One more thing the study’s own authors flag: estrogen-only regimens are appropriate only for women who’ve had a hysterectomy. If your uterus is still there, you’ll likely still need a progestogen for lining protection — which is exactly the trade-off your high-risk clinic should help you weigh, ideally before surgery when the hysterectomy question is still open.

Can you use HRT after breast cancer or cancer-related oophorectomy?

After breast cancer, systemic hormone therapy is generally not recommended, because the recurrence-safety evidence is unfavorable or insufficient. Any exceptional use is an oncology-led decision made after nonhormonal options have been tried. For persistent vaginal or urinary symptoms, low-dose vaginal estrogen may be considered after nonhormonal treatments fail, in coordination with your oncology team.

If this is you, an online HRT sign-up is not your starting point. Your cancer team is.

That’s not us being cautious to cover ourselves. It’s that cancer type, receptor status, stage, and your current treatment can reverse the general answer entirely, and none of that fits in a 10-minute intake form.

For urogenital symptoms specifically, there’s more room than many women are told. ACOG’s clinical consensus holds that nonhormonal methods are first-line— lubricants, hyaluronic acid, moisturizers — and that if those fail, low-dose vaginal estrogen may be considered through shared decision-making, in coordination with your oncologist. ACOG has also noted that data do not show an increased risk of recurrence among women with a personal history of breast cancer who use vaginal estrogen for these symptoms. That’s a real option worth raising with your team if you’ve been suffering in silence.

If cancer was suspected and pathology isn’t back yet: wait for the team reading it. “Cancer history” isn’t one category: breast, endometrial, and ovarian cancers each carry different considerations.

When might systemic HRT not be the right starting point?

A history of hormone-sensitive cancer, blood clots, stroke or heart attack, active liver disease, unexplained bleeding, or unresolved surgical pathology can require specialist review before systemic HRT. So can complex endometriosis or real uncertainty about what was removed. These don’t always mean “never” — they mean “not from a general online intake first.”

Situations requiring specialist review before online HRT:

Personal history of estrogen-sensitive or hormone-sensitive cancer
Prior blood clot, or a known inherited clotting condition
Prior stroke, heart attack, or established coronary disease
Active liver disease
Unexplained vaginal bleeding
Unresolved surgical pathology
Complex or extensive endometriosis
Current cancer-directed treatment
Genuine uncertainty about which organs remain

“Not the right starting point” is not the same as “never.” A specialist review can lead to a modified plan, nonhormonal treatment, local rather than systemic therapy, coordinated oncology follow-up — or a decision not to use HRT. All of those are better outcomes than a generic yes or a generic no.

Check whether your history needs a specialist first

The tool flags these situations rather than routing past them.

Patch, gel, or pill after oophorectomy: how does route change risk?

For most women, route is less important than finding appropriate HRT at all. But when clot risk matters, many clinicians favor a transdermal route: oral estrogen is associated with higher VTE risk than patches and gels in observational data. The stroke evidence is weaker. Pills remain a reasonable option for many women without elevated clot risk.

The key evidence comes from a 2015 systematic review and meta-analysis by Mohammed et al. in the Journal of Clinical Endocrinology & Metabolism. Oral estrogen was associated with higher risks of venous thromboembolism, ischemic stroke, and pulmonary embolism compared with transdermal estrogen in observational studies. This pattern has been replicated in subsequent population cohorts. It’s observational — not a randomized trial — but it’s consistent enough that clot history is now a standard reason to prefer a patch or gel.

Route matters differently at different ages. For younger women with no clot history and early surgical menopause, pill forms are often used and well-tolerated. For women closer to the usual menopause age, or with any cardiovascular or clotting risk factors, a transdermal form is typically preferred.

One thing the route debate doesn’t settle: whether you need a progestogen alongside the estrogen. That’s determined by your anatomy, not your route. See the progesterone section above for that framework.

What about testosterone after oophorectomy?

Oophorectomy removes a meaningful source of testosterone as well as estrogen — the same 2000 New England Journal of Medicine study that documented the estradiol decline also documented a roughly 50% decline in circulating testosterone after bilateral oophorectomy.

Despite that, testosterone is not routinely prescribedafter oophorectomy. When it is considered, it’s specifically for persistent, distressing low sexual desire after a thorough assessment has ruled out other causes and when estrogen and progestogen therapy is either not sufficient or not an option.

Evidence does not support testosterone for energy, mood, or general well-being. There is no FDA-approved testosterone product for women in the United States. All use is off-label, and testosterone is a Schedule III controlled substance requiring a prescription and monitoring. A 2025 review confirmed no regulator-approved product exists for women in the U.S.

If you want to explore this option, it should be part of a structured conversation with a menopause specialist, not an add-on from a general online intake.

Online care vs. in-person: which is right after oophorectomy?

Online HRT telehealth can work well for uncomplicated post-oophorectomy surgical menopause — if the service actually handles surgical menopause cases, reviews your operative and pathology records, serves your state, and provides real clinical follow-up rather than a checkout cart.

Online care may work if…

Uncomplicated bilateral oophorectomy, benign indication
Pathology is final and shows no cancer
No endometriosis, BRCA, or clotting history
Anatomy is clear (you know whether your uterus is in or out)
The service reviews operative/pathology records
You're in a state the provider serves
Real follow-up is available, not just a refill queue

Start in-person if…

Cancer history or pathology still pending
BRCA carrier, uncoordinated with a high-risk clinic
Complex or extensive endometriosis
Prior blood clots or stroke
Anatomy genuinely unclear (subtotal hysterectomy, records missing)
Current cancer-directed treatment
You want to be examined as part of the initial assessment

Not verified — treat as open: whether any named online provider specifically manages post-oophorectomy surgical menopause, reviews operative and pathology records, or handles subtotal hysterectomy and lining protection. Their public pages don’t establish it. That’s why the consultation checklist below is on this page rather than behind a sign-up. See our surgical menopause provider comparison for a verified breakdown.

Your consultation checklist

Free to use. No sign-up, no email. Bring this to your first appointment.

Records to obtain before your appointment

Operative report (confirms exactly which organs were removed)
Pathology report (especially if cancer, endometriosis, or BRCA)
Hospital discharge summary
Pre-surgery hormone levels (if measured)
Complete medication list (current + recent)
Insurance formulary or prior-authorization requirements
Family history relevant to breast cancer, clots, or heart disease

Questions to ask your clinician

Was my surgery unilateral or bilateral, and is the remaining ovary (if any) expected to function?
Is my uterus still intact, or was it a total vs. subtotal hysterectomy?
Does my pathology report indicate anything that changes which type of HRT is appropriate?
Do I have endometriosis that would affect the regimen, even without a uterus?
At my age, does guidance support starting hormone therapy now?
Which route (patch, gel, or pill) fits my risk history?
Do I need a progestogen, and if so, which type and why?
How long should I expect to stay on HRT, and when should I reassess?
Should I be referred to a specialist given my history?
What symptoms or changes should prompt me to contact you between appointments?

Not sure which provider models fit your state, coverage, and record-review needs? The tool checks all of those before suggesting a starting point.

See your best-fit starting care route and which provider models fit your state and coverage

What we verified — and what we didn’t

Verified against primary sources

Midi pricing and insurance terms (July 15, 2026)
FDA product list and labeling status (February 12, 2026 update)
JAMA Network Open 2026 BRCA cohort data and confidence intervals
BMS surgical menopause toolkit (September 2024)
BMS endometriosis induced-menopause guidance (February 2026)
ESHRE endometriosis guideline estrogen-only position (2022)
FDA endometrial cancer boxed-warning retention (November 2025 request)
Bone density data from Cooke et al. British Journal of Cancer 2011

Not verified — treat as open

Whether any named online provider specifically manages post-oophorectomy surgical menopause
Whether any named provider reviews operative and pathology records before prescribing
Whether any named provider handles subtotal hysterectomy and lining-protection edge cases
Any provider's current Medicaid/Medicare acceptance status beyond what we verified for Midi

This page is editorial research and is not medically reviewed by a clinician. It’s educational — not medical advice, and not a prescription. Read our medical review policy, methodology, and corrections policy.

Frequently asked questions

Do you have to take HRT after both ovaries are removed?: Not 'have to.' For women under about 45 with no contraindication, guidance generally supports offering it — for symptoms and to protect bone during years of missing estrogen. It's a medical decision made with a clinician, and it's ultimately your choice.
Do you need HRT after just one ovary is removed?: Not automatically. A functioning remaining ovary can keep producing hormones. If new menopausal symptoms appear, that's worth an evaluation rather than an assumption.
Do you need progesterone if you don't have a uterus?: Usually not for lining protection after a confirmed total hysterectomy. But a subtotal (supracervical) hysterectomy can leave residual lining tissue, and an endometriosis history often calls for combined therapy even without a uterus.
How soon after oophorectomy can HRT start?: There's no single interval. For benign surgery with final pathology and no contraindication, prompt initiation is commonly supported once your surgical team clears it. For endometriosis, no universal interval is established. For pending pathology or cancer, your treating team decides.
How long do you stay on HRT after early ovary removal?: Guidance commonly supports continuing until around the usual menopause age (about 51-52) when there's no contraindication, then reassessing. It doesn't have to be stopped automatically at a set age.
Is HRT safe after oophorectomy if I've had breast cancer?: Systemic HRT is generally not recommended after breast cancer; any exceptional use is oncology-led. For vaginal or urinary symptoms, nonhormonal treatments come first, with low-dose vaginal estrogen considered after those fail, in coordination with your oncology team.
Is HRT safe after a BRCA risk-reducing oophorectomy?: For carriers with no personal cancer history, it's commonly considered. A 2026 cohort of 919 women found no increased breast cancer risk with HRT after this surgery; a reduction appeared in the per-year duration analysis for estrogen-only use, not in the simple ever-use comparison. It's observational. Coordinate with your high-risk clinic, and note that an intact uterus still requires a progestogen.
Patch or pill after oophorectomy?: Many clinicians favor a patch or gel when clot risk matters — oral estrogen is associated with higher VTE risk in observational data. The stroke evidence is weaker. Pills remain reasonable for many women. It depends on your risk history.
Do you need testosterone after oophorectomy?: Not routinely. It may be considered for persistent, distressing low sexual desire after a full assessment. Evidence doesn't support it for energy, mood, or general well-being. There's no FDA-approved testosterone product for women in the U.S., it's off-label, and it's a Schedule III controlled substance requiring a prescription and monitoring.
Do I need blood tests before starting?: Not necessarily. If your records confirm both ovaries were removed, a hormone panel isn't needed to prove it. Tests should answer a specific question your clinician has.
Can an online provider manage HRT after oophorectomy?: Often yes for uncomplicated cases — if the service handles surgical menopause, reviews your records, serves your state, and provides real follow-up. If your case is cancer-, BRCA-, or endometriosis-complex, start with an in-person specialist.
Is compounded HRT the same as FDA-approved HRT?: No. Compounded hormones are prepared by a compounding pharmacy or outsourcing facility and are not FDA-approved. The FDA doesn't verify their safety, effectiveness, or quality before marketing. They aren't equivalent to approved products.
Will insurance cover it?: It depends on your plan, the product, the formulary, your pharmacy benefit, prior authorization, and whether the medication is compounded. Verify the actual product and billing route with your plan before treatment starts.

The bottom line

The first question after an oophorectomy isn’t “which HRT is best?” It’s what exactly was removed, what’s still there, why was the surgery done, and does my history point to routine care or a specialist? Answer those four, and the medication and provider questions get much simpler — and much less frightening.

You didn’t choose this crash course. But you can walk into your next appointment as the most prepared person in the room. That’s worth something.

Still not sure which HRT program is right for you? Take our free ~90-second matching quiz.

Find your best-fit HRT care path

About 90 seconds · No email required · No cost

Sources

Last verified: July 15, 2026. We check each source against its primary URL on a monthly or quarterly schedule. See our methodology for how we evaluate evidence.

Cleveland Clinic. Oophorectomy (unilateral vs. bilateral; bilateral removal before menopause causes menopause immediately). clevelandclinic.org
U.S. Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. February 12, 2026. fda.gov
U.S. Food and Drug Administration. Menopausal Hormone Therapies with Updated Prescribing Information (six products by category). Content current as of February 12, 2026. fda.gov
U.S. Food and Drug Administration. FDA Requests Labeling Changes for Menopausal Hormone Therapies (November 10, 2025; endometrial-cancer boxed warning retained for systemic estrogen-alone). fda.gov
U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. fda.gov
The Menopause Society (formerly NAMS). 2022 Hormone Therapy Position Statement. menopause.org
British Menopause Society. Surgical Menopause: a toolkit for healthcare professionals(September 2024) — offer HRT to women under 45 until at least 51 absent contraindications. thebms.org.uk
British Menopause Society. Induced Menopause in Women with Endometriosis(February 2026) — no agreed universal interval for starting HRT post-surgery. thebms.org.uk
ESHRE. Guideline: Endometriosis(2022) — avoid estrogen-only regimens in women with an endometriosis history. eshre.eu
Jakson I, et al. Endometriosis and menopause — management strategies based on clinical scenarios. Acta Obstet Gynecol Scand. 2023. obgyn.onlinelibrary.wiley.com
Regev-Sadeh S, et al. Hormone Therapy After Oophorectomy and Breast Cancer Risk in Women With BRCA Pathogenic Variant. JAMA Netw Open. 2026;9(4):e265648. jamanetwork.com
Kotsopoulos J, et al. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncol. 2018;4(8):1059-1065. jamanetwork.com
American College of Obstetricians and Gynecologists. Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer: Clinical Consensus. Obstet Gynecol. 2021;138:950-960. acog.org
ACOG Committee Opinion No. 659. The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer. pubmed.ncbi.nlm.nih.gov
Mohammed K, et al. Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2015;100(11):4012-4020. academic.oup.com
Shifren JL, et al. Transdermal Testosterone Treatment in Women With Impaired Sexual Function After Oophorectomy. N Engl J Med. 2000;343:682-688. (~50% testosterone and ~80% estradiol decline after bilateral oophorectomy.)nejm.org
Cooke DA, et al. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy. Br J Cancer. 2011. (37/78 = 47% vs 5/31 = 16% low bone density by estrogen-deprivation exposure.)nature.com
Should We Consider Testosterone Therapy in Oophorectomized Women? ScienceDirect, 2025. (No regulator-approved testosterone product for women in the U.S.)sciencedirect.com
Hormone Replacement Therapy in Young Women With Surgical Primary Ovarian Insufficiency. PMC5248494. pmc.ncbi.nlm.nih.gov
Midi Health. Pricing & Insurance (self-pay $250 initial / $150 continued care; PPO in-network; Medicaid and Medi-Cal not treated; Medicare not covered, self-pay permitted without claims; HSA/FSA accepted). Verified July 15, 2026. joinmidi.com

Related on The HRT Index

HRT After Hysterectomy HRT Contraindications HRT Benefits & Risks HRT After Blood Clot HRT After Stroke Vaginal Estrogen Guide Nonhormonal Options HRT Cost & Insurance 2026 Best Online HRT for Surgical Menopause Health Data Privacy

Keep reading: